This is a routine procedural ruling with no material impact on Moderna's stock. The underlying patent litigation continues on its existing schedule. Monitor for claim construction rulings or summary judgment motions later in 2026, which would carry substantive risk.
MRNA drugs
MRNA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 17 $61.80entry
- T+1 · 5mo ago +3.50%α +2.46% · $63.96
- T+5 · 5mo ago −3.32%α −2.67% · $59.75
- T+20 · 4mo ago +0.03%α −0.54% · $61.82
- T+60 · 2mo ago +137.36%α +134.41% · $146.69
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A Special Master in the District of Delaware denied GSK's motion to limit third-party inventor depositions to 10 combined hours across its patent infringement cases against Pfizer/BioNTech and Moderna. The ruling allows each defendant group up to 7 hours per inventor witness, preserving full examination rights for key inventors Dr. Geall and Dr. Mandl. This is a procedural discovery ruling with no financial exposure, no injunction, and no change to the underlying patent litigation merits.
Court Ruling Details
Key Facts
- GSK's motion to limit defendants to 10 combined hours of third-party inventor depositions was DENIED
- Each defendant group (Pfizer/BioNTech and Moderna) retains the right to up to 7 hours per inventor witness under FRCP 30(d)(1)
- The ruling concerns two key witnesses: Dr. Andrew Geall (named inventor on all asserted patents) and Dr. Christian Mandl
- Fact discovery closes July 29, 2026, in all three related actions
- No damages, injunction, or liability determination was made, purely a scheduling/discovery dispute
Financial Impact
No financial impact, procedural discovery ruling only
Risk Factors
- No new risks from this ruling, the underlying patent infringement cases remain pending with no liability determination
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3rrqn0ol-MRNA |
Track record
26 reports on MRNA
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers